vs
Certara, Inc.（CERT）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是Certara, Inc.的1.2倍（$127.1M vs $103.6M），再鼎医药同比增速更快（17.1% vs 3.3%），Certara, Inc.自由现金流更多（$27.8M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 3.6%）
Certara是全球领先的生物制药软件及咨询服务提供商，专注于建模模拟、监管科学领域的解决方案，服务药企、生物技术企业及医疗相关方，覆盖药物研发全周期，助力加快新疗法上市，降低研发风险与综合成本。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
CERT vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.2倍
$103.6M
营收增速更快
ZLAB
高出13.8%
3.3%
自由现金流更多
CERT
多$54.5M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
3.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $103.6M | $127.1M |
| 净利润 | $-5.9M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 0.8% | -54.6% |
| 净利率 | -5.7% | — |
| 营收同比 | 3.3% | 17.1% |
| 净利润同比 | -189.6% | — |
| 每股收益（稀释后） | $-0.04 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CERTZLAB
| Q4 25 | $103.6M | $127.1M | ||
| Q3 25 | $104.6M | $115.4M | ||
| Q2 25 | $104.6M | $109.1M | ||
| Q1 25 | $106.0M | $105.7M | ||
| Q4 24 | $100.4M | $108.5M | ||
| Q3 24 | $94.8M | $101.8M | ||
| Q2 24 | $93.3M | $100.1M | ||
| Q1 24 | $96.7M | $87.1M |
净利润CERTZLAB
| Q4 25 | $-5.9M | — | ||
| Q3 25 | $1.5M | $-36.0M | ||
| Q2 25 | $-2.0M | $-40.7M | ||
| Q1 25 | $4.7M | $-48.4M | ||
| Q4 24 | $6.6M | — | ||
| Q3 24 | $-1.4M | $-41.7M | ||
| Q2 24 | $-12.6M | $-80.3M | ||
| Q1 24 | $-4.7M | $-53.5M |
毛利率CERTZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率CERTZLAB
| Q4 25 | 0.8% | -54.6% | ||
| Q3 25 | 2.9% | -42.3% | ||
| Q2 25 | 9.1% | -50.3% | ||
| Q1 25 | 7.2% | -53.3% | ||
| Q4 24 | 6.0% | -62.6% | ||
| Q3 24 | 2.7% | -66.6% | ||
| Q2 24 | -9.7% | -76.0% | ||
| Q1 24 | -1.3% | -80.7% |
净利率CERTZLAB
| Q4 25 | -5.7% | — | ||
| Q3 25 | 1.5% | -31.2% | ||
| Q2 25 | -1.9% | -37.3% | ||
| Q1 25 | 4.5% | -45.8% | ||
| Q4 24 | 6.6% | — | ||
| Q3 24 | -1.4% | -40.9% | ||
| Q2 24 | -13.5% | -80.2% | ||
| Q1 24 | -4.8% | -61.4% |
每股收益（稀释后）CERTZLAB
| Q4 25 | $-0.04 | $-0.05 | ||
| Q3 25 | $0.01 | $-0.03 | ||
| Q2 25 | $-0.01 | $-0.04 | ||
| Q1 25 | $0.03 | $-0.04 | ||
| Q4 24 | $0.04 | $-0.09 | ||
| Q3 24 | $-0.01 | $-0.04 | ||
| Q2 24 | $-0.08 | $-0.08 | ||
| Q1 24 | $-0.03 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $189.4M | $689.6M |
| 总债务越低越好 | $293.1M | — |
| 股东权益账面价值 | $1.1B | $715.5M |
| 总资产 | $1.6B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.28× | — |
8季度趋势，按日历期对齐
现金及短期投资CERTZLAB
| Q4 25 | $189.4M | $689.6M | ||
| Q3 25 | $172.7M | $717.2M | ||
| Q2 25 | $162.3M | $732.2M | ||
| Q1 25 | $179.1M | $757.3M | ||
| Q4 24 | $179.2M | $779.7M | ||
| Q3 24 | $233.0M | $616.1M | ||
| Q2 24 | $224.6M | $630.0M | ||
| Q1 24 | $224.8M | $650.8M |
总债务CERTZLAB
| Q4 25 | $293.1M | — | ||
| Q3 25 | $293.5M | — | ||
| Q2 25 | $294.2M | — | ||
| Q1 25 | $294.8M | — | ||
| Q4 24 | $295.4M | — | ||
| Q3 24 | $296.1M | — | ||
| Q2 24 | $296.7M | — | ||
| Q1 24 | $290.8M | — |
股东权益CERTZLAB
| Q4 25 | $1.1B | $715.5M | ||
| Q3 25 | $1.1B | $759.9M | ||
| Q2 25 | $1.1B | $791.7M | ||
| Q1 25 | $1.1B | $810.8M | ||
| Q4 24 | $1.1B | $840.9M | ||
| Q3 24 | $1.1B | $667.7M | ||
| Q2 24 | $1.0B | $704.2M | ||
| Q1 24 | $1.1B | $762.2M |
总资产CERTZLAB
| Q4 25 | $1.6B | $1.2B | ||
| Q3 25 | $1.5B | $1.2B | ||
| Q2 25 | $1.5B | $1.2B | ||
| Q1 25 | $1.6B | $1.2B | ||
| Q4 24 | $1.6B | $1.2B | ||
| Q3 24 | $1.5B | $985.3M | ||
| Q2 24 | $1.5B | $987.4M | ||
| Q1 24 | $1.5B | $988.4M |
负债/权益比CERTZLAB
| Q4 25 | 0.28× | — | ||
| Q3 25 | 0.28× | — | ||
| Q2 25 | 0.27× | — | ||
| Q1 25 | 0.27× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 0.28× | — | ||
| Q2 24 | 0.28× | — | ||
| Q1 24 | 0.28× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.8M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $27.8M | $-26.7M |
| 自由现金流率自由现金流/营收 | 26.8% | -21.0% |
| 资本支出强度资本支出/营收 | 1.0% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $94.4M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流CERTZLAB
| Q4 25 | $28.8M | $-26.0M | ||
| Q3 25 | $32.3M | $-32.0M | ||
| Q2 25 | $17.8M | $-31.0M | ||
| Q1 25 | $17.4M | $-61.7M | ||
| Q4 24 | $49.4M | $-55.8M | ||
| Q3 24 | $17.0M | $-26.8M | ||
| Q2 24 | $9.8M | $-42.2M | ||
| Q1 24 | $4.3M | $-90.1M |
自由现金流CERTZLAB
| Q4 25 | $27.8M | $-26.7M | ||
| Q3 25 | $32.1M | $-35.0M | ||
| Q2 25 | $17.8M | $-33.9M | ||
| Q1 25 | $16.8M | $-63.2M | ||
| Q4 24 | $49.0M | $-58.4M | ||
| Q3 24 | $16.8M | $-28.2M | ||
| Q2 24 | $9.4M | $-42.9M | ||
| Q1 24 | $3.7M | $-91.1M |
自由现金流率CERTZLAB
| Q4 25 | 26.8% | -21.0% | ||
| Q3 25 | 30.7% | -30.4% | ||
| Q2 25 | 17.0% | -31.1% | ||
| Q1 25 | 15.8% | -59.9% | ||
| Q4 24 | 48.8% | -53.8% | ||
| Q3 24 | 17.7% | -27.7% | ||
| Q2 24 | 10.1% | -42.9% | ||
| Q1 24 | 3.8% | -104.5% |
资本支出强度CERTZLAB
| Q4 25 | 1.0% | 0.5% | ||
| Q3 25 | 0.2% | 2.6% | ||
| Q2 25 | 0.1% | 2.6% | ||
| Q1 25 | 0.6% | 1.5% | ||
| Q4 24 | 0.4% | 2.4% | ||
| Q3 24 | 0.2% | 1.3% | ||
| Q2 24 | 0.5% | 0.7% | ||
| Q1 24 | 0.6% | 1.1% |
现金转化率CERTZLAB
| Q4 25 | — | — | ||
| Q3 25 | 21.19× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.66× | — | ||
| Q4 24 | 7.51× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CERT
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
